BARINTHUS BIOTHERAPEUTICS PLC - AMERICAN DEPOSITAR

0,8947

22-ноября-24 16:44:58

15 мин. задержка

Акции

-0,0936

-9,47%

Сегодняшний диапазон

0,8947 - 1,0200

ISIN

N/A

Источник

NASDAQ

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

15 ноя 2024 11:02:00 Источник Nasdaq GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

15 ноя 2024 11:01:00 Источник Nasdaq GlobeNewswire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

06 ноя 2024 08:00:01 Источник Nasdaq GlobeNewswire
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

31 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

01 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

24 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

08 авг 2024 08:00:01 Источник Nasdaq GlobeNewswire
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

12 июн 2024 16:01:00 Источник Nasdaq GlobeNewswire
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

06 июн 2024 11:15:00 Источник Nasdaq GlobeNewswire
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

22 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

13 май 2024 08:00:01 Источник Nasdaq GlobeNewswire
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

01 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

18 апр 2024 16:10:00 Источник Nasdaq GlobeNewswire
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

20 мар 2024 08:15:23 Источник Nasdaq GlobeNewswire
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

05 янв 2024 16:01:00 Источник Nasdaq GlobeNewswire
New partnership aims to advance vaccine against MERS coronavirus

21 дек 2023 07:31:16 Источник Nasdaq GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

09 ноя 2023 16:24:43 Источник Nasdaq GlobeNewswire
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

09 ноя 2023 16:01:00 Источник Nasdaq GlobeNewswire
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

06 ноя 2023 09:05:56 Источник Nasdaq GlobeNewswire
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

13 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.